Dopamine receptor antagonism is a common mechanism underlying the therapeutic efficacy of all classical antipsychotic drugs. It is also thought to underlie the propensity of these agents to induce the movement disorder, tardive dyskinesia (TD), in one fifth of chronically exposed schizophrenia patients. We examined the polymorphic serine to glycine substitution in the first exon of the gene encoding the dopamine D3 receptor (DRD3) inn 53 schizophrenia patients with TD, 63 matched patients with similar antipsychotic exposure but no TD and 117 normal controls. There was a difference in allele frequency that was of borderline significance (P = 0.055), due to an excess of the DRD3 gly allele (allele 2) in the schizophrenia patients with TD. The difference in genotype distribution among the groups was highly significant ( The dopamine D3 receptor gene (DRD3) has been a focus of intense interest in psychiatric genetics for a number of years, primarily in relation to schizophrenia. This interest has not waned in spite of a discouraging disparity in the results obtained. The human DRD3 gene was localized to 3q13.3 by in situ hybridization.
Dopamine receptor antagonism is a common mechanism underlying the therapeutic efficacy of all classical antipsychotic drugs. It is also thought to underlie the propensity of these agents to induce the movement disorder, tardive dyskinesia (TD), in one fifth of chronically exposed schizophrenia patients. We examined the polymorphic serine to glycine substitution in the first exon of the gene encoding the dopamine D3 receptor (DRD3) inn 53 schizophrenia patients with TD, 63 matched patients with similar antipsychotic exposure but no TD and 117 normal controls. There was a difference in allele frequency that was of borderline significance (P = 0.055), due to an excess of the DRD3 gly allele (allele 2) in the schizophrenia patients with TD. The difference in genotype distribution among the groups was highly significant ( Comparing the schizophrenia patients with and without TD, genotypes containing the gly allele (DRD3 ser-gly and DRD3 gly-gly genotypes combined) were significantly associated with dyskinesia (OR = 2.62, 95% CI 1.18-5.59, P = 0.02). DRD3 genotype and age at first antipsychotic treatment contributed significantly to total score on the Abnormal Involuntary Movements Scale (AIMS). The contribution of DRD3 to the variance in AIMS total was 5.2% and the total proportion of the variance accounted for by these two variables together was 11.9%. These results support and extend the report by Steen et al (1997) of an association between DRD3 and TD in schizophrenia patients.
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The dopamine D3 receptor gene (DRD3) has been a focus of intense interest in psychiatric genetics for a number of years, primarily in relation to schizophrenia. This interest has not waned in spite of a discouraging disparity in the results obtained. The human DRD3 gene was localized to 3q13.3 by in situ hybridization. 1 A polymorphic site in exon 1 of DRD3 gives rise to a serine to glycine substitution in the N terminal extracellular domain of the receptor protein. This creates a BalI (MscI) restriction enzyme site. 2 Numerous groups have examined linkage and association of schizophrenia with DRD3. Linkage studies have been uniformly negative. Over 30 studies (mostly population-but also family-based) were included by Williams et al 3 in a meta-analysis that yielded evidence for a modest association with homozygosity for either DRD3 ser (allele 1) or DRD3 gly (allele 2) (OR 1.21, 95% CI 1.07-1.35, P = 0.0009). Association of a disease with homozygosity for either allele of a candidate gene is difficult to conceptualize, although such an association has also been reported for an amino acid substitution in the prion protein gene in Creutzfeldt-Jakob disease. 4 Contemporaneously, with the Williams et al 3 metaanalysis, a large population-based study found no evidence for association of schizophrenia with DRD3. 5 Subsequently, Krebs et al 6 found an association of homozygosity with substance abuse in a small sample of schizophrenia patients and Duaux et al 7 in nonschizophrenic opiate abusers.
A different approach was provided by the findings of Steen et al 8 who reported association of DRD3 allele 2 (DRD3 gly ) and tardive dyskinesia (TD) in schizophrenia patients and a significant excess of 2-2 (DRD3 gly-gly ) homozygotes. TD is a well recognized adverse effect of long-term administration of antipsychotic drugs that are dopamine receptor blockers. It is characterized by involuntary, choreoathetotic movements that develop in about one fifth of patients chronically exposed to these drugs. 9 While the majority of patients do not develop TD despite decades of exposure to large cumulative doses, susceptible patients may be affected even after relatively brief exposure. Studied risk factors for TD include drugrelated variables such as cumulative dose and dopamine D2 receptor affinity, as well as patient-related risk factors such as age and gender. 10 These predict only a part of the variance in the incidence of TD. Most of the basis for the large individual variability in susceptibility to TD is undefined, suggesting a potential role for a largely unexplored pharmacogenetic component.
The findings of Steen et al 8 suggest that previous reports of an association of DRD3 with schizophrenia may have been confounded by variable rates of TDprone subjects in the samples examined. This explanation would be particularly relevant to studies that found an association between schizophrenia and allele 2 of DRD3 (DRD3 gly ). Such an observation was reported by Kennedy et al 11 and by our group.
12
In the current study, we examined a new sample of schizophrenia patients and controls. The schizophrenia patients underwent evaluation for dyskinesia using the Abnormal Involuntary Movements Scale (AIMS) and were also rated for current clinical and extrapyramidal symptoms. Our results support the direction suggested by Steen et al 8 in regard to association between DRD3 and TD, and also raise the possibility that predisposition to dyskinesia may be characteristic of a subtype of schizophrenia that has other specific clinical manifestations.
Materials and methods

Clinical
Patients from the participating centers, who fulfilled inclusion/exclusion criteria, were screened for TD, according to the Research Diagnostic Criteria for Tardvie Dyskinesia (RDC-TD). 13 The inclusion criteria were: (1) diagnosis of schizophrenia according to DSM-IV criteria; (2) age 18-65 years; (3) male or female; (4) lifetime duration of exposure to antipsychotic drugs of at least 5 years; (5) Jewish, of definite Ashkenazi or nonAshkenazi origin (ie both parents of Ashkenazi or nonAshkenazi origin); (6) stable dose of antipsychotic and anticholinergic medication for 3 months prior to evaluation; (7) willingness to participate in the study and to give written informed consent. Patients with a lifetime history of alcohol/substance dependence or of abuse within the last 5 years, active or past medical or neurologic illness that might confound study assessments or of mixed or uncertain ethnic origin, were excluded. The study was approved by the Internal Review Board (Helsinki Committee) of the Hadassah -Hebrew University Medical Center.
Instruments of evaluation included standardized checklists for the diagnosis of schizophrenia according to DSM-IV on the basis of clinical examination and case notes, the Abnormal Involuntary Movement Scale (AIMS), 14 the Positive and Negative Symptom Scale (PANSS) 15 and the Simpson Angus scale 16 for extrapyramidal signns. To insure consistency in ratings of TD, all raters achieved interrater reliability of Ͼ0.90 with the investigator bearing overall responsibility for the TD assessments (UHL), based on the same series of patients, before commencing the study. Patients who received a rating of mild dyskinesia in two or more body areas, or of moderate or severe dyskinesia in any body area on the basis of the AIMS, were categorized as having TD according to RDC-TD. Patients were assessed only once. Therefore, the diagnosis of TD in our sample corresponds to the category termed 'crosssectional TD' by Steen et al. 8 A total of 57 patients who fulfilled RDC-TD 13 and 80 patients without TD were recruited. The TD and non-TD groups were then matched (prior to genotyping) on the basis of the following criteria: age, gender, ethnic origin (Ashkenazi or non-Ashkenazi), years of anti-psychotic drug treatment (range 2.5 years) and dose of antipsychotic medication during the preceding 3 months, in chlorpromazine units. Background and clinical characteristics of the matched groups of schizophrenia patients are shown in Table 1 . With the exception of age at first antipsychotic drug treatment (for which patients were not matched a priori) there was no difference between the groups in background characteristics.
Control subjects (aged 35 years or older, n = 117, 55 (47%) male) were recruited from neighborhood community centers and from the administrative, technical and service staff of the Hadassah -Hebrew University Medical Center. All control subjects gave written informed consent. Personal or family history of Axis I DSM-IV psychiatric disorder was excluded by a screening interview. Only Jewish control subjects with clearly defined Ashkenazi (n = 60, 51.3%) or non-Ashkenazi (n = 57, 49.7%) origin (both parents Ashkenazi or nonAshkenazi) were included. There were no significant differences between the control and the schizophrenia groups in gender (
, P Ͼ 0.1) but the controls were significantly younger (44 ± 9.4 years) than the two schizophrenia groups (SCZ -no TD 49.6 ± 10.7, SCZ-TD 52.1 ± 11.6 years; F = 14.1, d.f. 2, P Ͻ 0.0001) although all the controls were aged 35 years or more.
Laboratory
DNA was extracted from fresh whole blood samples anticoagulated with EDTA, using Boehringer Mannheim (Mannheim, Germany) DNA extraction kits for mammalian blood. Genotyping was performed without knowledge of the clinical status of the subjects. PCR amplification was carried out using an MJ Research PTC-200 thermocycler (Watertown, MA, USA), with the following primers flanking exon 1 of the D3 receptor gene: 5Ј-GCTCTATCTCCAACT CTCACA-3Ј and 5Ј-AAGTCTACTCACCTCCAGGTA-3Ј. 2 PCR amplification was performed in a total volume of 20 l containing 50 ng genomic DNA, 1 U Taq Polymerase (Boehringer Mannheim), 2 l 10 × PCR buffer, 10 pmol of each primer, 160 mM of each dNTP, and 0.01% of gelatin. Following denaturation of 95°C for 5 Values are given as mean ± SD or n (%). min, thirty-five cycles were performed with a profile of 95°C for 30 s, 56°C for 40 s and 72°C for 40 s. This profile is followed by extension at 72°C for 5 min. The PCR products were then digested with the MscI restriction endonuclease (New England Biolabs, Beverly, MA, USA) for 4 h at 37°C, and digestion products were analyzed following electrophoresis in 3% Metaphore agarose gel (FMC Bioproducts, Rockland, ME, USA) stained with ethidium bromide under UV light against a molecular weight ladder. Restriction results in a 304-bp product (allele 1 Ser-9) or 206-bp and 98-bp products (allele 2 Gly-9) as well as constant bands of 111 bp and 47 bp. Some of the typings were additionally verified by employing an alternative primer set residing internal to the above primers in the first exon: 17 5Ј-TGGGCTATGGCATCTCTGAG-3Ј and 5Ј-CCACCA GCAAGCAAGTCTGCCACA-3Ј. PCR amplification and MscI restriction were performed using the above conditions to yield an undigested product of 241 bp in size. MscI digestion produced a constant 111-bp fragment with a 130-bp fragment representing allele 1 or 98-bp and 32-bp fragments for allele 2.
Statistics
For categorical analyses, maximum likelihood chisquare statistics were used. Bivariate relations between continuous variables were examined with the Pearson correlation coefficient and multivariate relationships by stepwise multiple regression. Differences between groups on single, continuous variables were evaluated with Student's t-tests, analysis of variance (ANOVA) or analysis of covariance (ANCOVA). Values are given as mean ± standard deviation (SD). Significance levels are for two-tailed tests; P values Ͻ0.05 were regarded as significant. The SAS program and Statistica for Windows were used for analyses. Hardy-Weinberg equilibrium and relative risk were tested by the utility programs of J Ott.
Results
To determine whether ethnic stratification might influence the results, we initially compared DRD3 allele frequency and genotype distribution in the Ashkenazi and non-Ashkenazi controls. There were no significant differences (alleles Table 2 shows the distribution of alleles and genotypes in the three subject groups. There was a difference in allele frequency that was of borderline significance (P = 0.055), due to an excess of the gly allele in the schizophrenia patients with TD. This difference was also demonstrable in the Ashkenazi subjects alone ( Comparing the schizophrenia patients with and without TD, genotypes containing the gly allele (DRD3 ser-gly and DRD3 gly-gly genotypes combined) were significantly associated with dyskinesia (OR = 2.62, 95% CI 1.18-5.59, P = 0.02). Table 3 shows a comparison (by analysis of covariance, controlling for age at first antipsychotic treatment) of mean ± standard deviation AIMS total and subscale scores in patients grouped according to the presence of the DRD3 gly allele in their genotypes (DRD3 ser-ser vs DRD3 ser-gly/gly-gly ). Patients carrying genotypes with the DRD3 gly allele had significantly higher AIMS total (P = 0.02), trunk (P = 0.01) and incapacitation (P = 0.03) scores than those homozygous for the DRD3 ser allele and the difference in orofacial dyskinesia score was of borderline significance (P = 0.052). In order to quantify the contribution of DRD3 genotype and other background and clinical variables to dyskinesia severity, we performed stepwise multiple regressions. The various AIMS subscales were significantly related to each other and to the total AIMS score. Therefore, AIMS total was used as the dependent variable. The independent variables were DRD3 genotype (DRD3 ser-ser or DRD3 ser-gly/gly-gly ), age, gender, ethnicity, age at first antipsychotic treatment, years of antipsychotic treatment, antipsychotic dose during the preceding 3 months in chloropromazine units and history of cigarette smoking. The results are shown in Table 4 . Only age at first antipsychotic treatment and DRD3 genotype contributed significantly to AIMS total score. The contribution of DRD3 to the variance in AIMS total was 5.2% and the total proportion of the variance accounted for by these two variables together was 11.9%. Similar regressions were performed for PANSS total score (the subscales and total scores on this scale were highly interrelated) and for the total score on the Simpson Angus scale. No variable contributed significantly to PANSS total. Simpson Angus total was significantly related to age only (P = 0.03, r 2 = 0.03). We undertook additional exploratory analyses in order to determine whether any further characteristics of a schizophrenia phenotype associated with DRD3 genotypes containing the DRD3 gly allele, could be identified (Table 5 ). There was no difference (by ANCOVA with age at first antipsychotic treatment as covariate) between PANSS total or subscale scores in patients with the DRD3 ser-ser compared to the DRD3 sergly/gly-gly genotypes. However (Table 4) , AIMS total score was significantly correlated with PANSS total score and with all the PANSS subscale scores in patients with the DRD3 ser-gly/gly-gly genotype. Among patients with the DRD3 ser-ser genotype, AIMS total was not significantly correlated with PANSS total nor any of the PANSS subscales. Simpson Angus total score was significantly related to AIMS total score in patients with all genotypes.
Discussion
We have reported a significant association between the DRD3 gene and the presence of dyskinesia in patients Scores are mean ± standard deviation. For Incapacitation, score of one subject was missing. with chronic schizophrenia. This association manifested as an increased likelihood of dyskinesia in schizophrenia patients with genotypes that include the DRD3 gly allele (allele 2). The genotypic difference was demonstrated in an overall comparison between schizophrenia patients and controls, but this was due to the contribution of the schizophrenia patients with dyskinesia. Patients carrying the DRD3 gly allele in their genotypes (DRD3 ser-gly or DRD3 gly-gly ) had higher AIMS total, orofacial, trunk and incapacitation scores. The contribution of DRD3 to variance in AIMS scores, reflecting dyskinesia, was small (5.2%) but significant (P = 0.006). We also observed a significant correlation between AIMS scores and PANSS total and subscale scores in patients whose genotypes included at least one DRD3 gly allele but not in patients homozygous for the DRD3 ser allele (allele 2). Our findings are unlikely to be due to ethnic stratification. There was no significant difference in DRD3 allele frequency or genotype distribution between the Ashkenazi and non-Ashkenazi controls, schizophrenia patients without TD and schizophrenia patients with TD. The ethnic distribution of the control and schizophrenia groups was similar and also the gender distribution. Moreover, the finding was demonstrated separately in the two ethnic groups. The control group was younger than both schizophrenia groups but older than 35 years and thus past the age of risk for schizophrenia. A very high degree of matching was achieved between the schizophrenia patients with and without TD, thus controlling for other variables that might differentially predispose to TD. There was a small but significant difference in age at first antipsychotic treatment. This variable has not generally been reported as predisposing to TD. However, stepwise multiple regression analysis showed that DRD3 contributed to dyskinesia independently of the contribution of age at first antipsychotic treatment.
A valid criticism of our study is that dyskinesia was assessed only once and TD could thus be diagnosed only at a probable level according to RDC-TD. 13 Our findings correspond to those of the cross-sectional analysis reported by Steen et al 8 in which association with DRD3 was demonstrated. We were also able to demonstrate the relationship parametrically using AIMS scores as a continuous variable.
An important difference between our study and that of Steen et al 8 is that the strongest finding of Steen et al 8 was association of TD with homozygosity for the DRD3 gly allele, while in our study the association was due to an excess of heterozygotes in the schizophrenia patients with TD. While our control group and our schizophrenia patients without TD were in HardyWeinberg equilibrium (HWE) for DRD3, our schizophrenia/TD patients were not. Thus, our finding could theoretically be attributed to an anomalous distribution of genotypes in the schizophrenia patients with TD due to spurious causes. We may hypothesize two possible explanations-either a sampling bias due to the fact the patients were selected for the presence of TD or an influence of the TD trait on HWE. Usually, the selection of samples with a feature associated with a marker causes a rise of the associated allele frequency but HWE is maintained. In our case only the heterozygous subjects were in excess; we may hypothesize that only the DRD3 ser-gly genotype is associated with the TD trait therefore distorting HWE but this is not consistent with the findings of Steen et al. 8 A more likely explanation is a bias due to the small sample size. It is feasible that both DRD3 ser-gly and DRD3 gly-gly are susceptibility factors for TD but our sample had enough power to detect only the DRD3 ser-gly genotype effect. In fact, we had a high power (0.98) to detect the observed difference (OR = 4.6, effect size w = 0.33) between TD subjects and controls regarding the DRD3 ser-gly genotype but when we consider DRD3 gly-gly , we had the same power to detect an OR of 5.4 that corresponds to a 50% frequency of the DRD3 gly-gly genotype among schizophrenia patients with TD. Therefore we may have missed a smaller effect. Nevertheless, it should be noted that our finding of DRD3 ser-gly genotype excess in schizophrenia patients with TD was demonstrable when restricting the analysis to subjects of Ashkenazi origin and there was no significant deviation from HWE in the schizophrenia patients with TD who were of Ashkenazi origin. Finally, parametric analysis comparing AIMS scores in patients carrying the DRD3 ser-ser genotype to those carrying the DRD3 ser-gly or DRD3 gly-gly genotype, showed significantly higher scores in those carrying the DRD3 ser-gly or DRD3 gly-gly genotype. This analysis would not be as sensitive to spurious influences on genotype distribution as would a comparison of genotype distribution based on a categorical definition of the phenotype.
The in vivo functional significance of the polymorphic Ser9Gly site is unknown. DRD3 receptor-binding analysis of Chinese hamster ovary (CHO) cells infected with Semliki Forest Virus to express either the wildtype cDNA or a recombinant Ser9Gly or both, showed similar pharmacological properties for several D3 receptor ligands. 18 However, the DRD3 gly-gly homozygote showed a significantly higher binding affinity for dopamine whereas heterozygotes (ie doubly infected cells) were not significantly different from the wildtype. In addition, both DRD3 gly-gly homozygotes and DRD3 ser-gly heterozygotes showed significantly higher binding affinity for the selective D3 ligand GR99841, compared to the wild-type receptor. 19 While these results do not allow a straightforward extrapolation with regard to the biological significance of heterozygote vs homozygote status, they speak for either examining DRD3 gly-gly homozygotes against all other genotypes or four grouping DRD3 gly-gly homozygotes and DRD3 ser-gly heterozygotes against wild-type homozygotes. Such extrapolations should be taken with caution, however, as these results were obtained in an in vitro recombinant system not necessarily reflecting in vivo receptor status in the brain.
An association between neurocognitive deficits and TD has been described, and it has also been suggested that patients with more pronounced negative symptoms may be more vulnerable to TD and that these features may represent associated aspects of a particular schizophrenia subtype. 19 Whereas our results do not show a direct association of DRD3 genotype with PANSS score, AIMS and PANSS scores were significantly correlated only in patients with the DRD3 ser-gly or DRD3 gly (1-2/2-2) genotypes. The correlation was not limited to negative or cognitive symptoms but encompassed positive features as well. Among patients with the DRD3 ser-gly (1-1) genotype, AIMS total was not significantly correlated with PANSS total nor any of the PANSS subscales. Although preliminary, these results may be interpreted to support a genetic contribution of DRD3 genotype to a subtype of schizophrenia characterized by greater severity across a range of symptoms as well as predisposition to TD. Previous inconclusive results of attempts to associate DRD3 genotype and schizophrenia, may have been confounded by differing rates of patients prone to dykinesia in the samples, as proposed by Steen et al. 8 A useful approach to further address this possibility would be to clinically dissect schizophrenia samples according to DRD3 genotype, with our findings predicting higher dyskinesia and PANSS scores in patients carrying the DRD3 gly (2) allele. This approach, incorporating the study of additional candidate genes according to a similar strategy, could help shed light on the pathophysiology of TD, and perhaps lead to a better understanding of the genetic heterogeneity underlying schizophrenia.
